Patients treated with procainamide for cardiac arrhythmias commonly develop anti-histone antibodies and often frank symptoms of systemic lupus erythematosus. The mechanism by which this etiologic agent elicits autoantibodies and lupus symptoms is unknown and is the long term objective of this investigation. Insights will be sought by a systematic evaluation of the clinical and laboratory changes which take place in a group of patients prospectively studied during development of signs and symptoms. Preliminary results suggest that highly restricted autoantibody responses occur in some patients.
We aim to examine this phenomenon by delineating the precise specificity of anti-histone antibodies and enumerating the antibody populations within a serum. This will be done by solid phase adsorption on individual histones and by examination of the histone binding specificities of antibodies affinity purified on a panel of individual histones. Mouse monoclonal antibodies having a variety of histone-binding specificities will be used to compete with human antibodies for binding to the same antigen. Determination of the number and kinds of drug-elicited autoantibodies will provide the framework for possible models for antibody genesis at the B-cell level. The role of anti-histone antibodies in the pathogenesis of drug-induced lupus will be studied in context of the complement system. The capacity of different types of anti-histone antibodies and different forms of histones to participate in complement activation will be investigated, and evidence for complement activation in vivo will be sought. Relationships among these parameters will be of predictive value in managing drug-treated patients and provide insights into the pathogenic mechanisms which underly this type of systemic autoimmune disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR034358-03
Application #
3156804
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1984-09-01
Project End
1987-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92037
Burlingame, R W; Rubin, R L; Rosenberg, A M (1993) Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum 36:836-41
Rubin, R L; Bell, S A; Burlingame, R W (1992) Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 90:165-73
Rubin, R L (1992) Autoantibody specificity in drug-induced lupus and neutrophil-mediated metabolism of lupus-inducing drugs. Clin Biochem 25:223-34
Burlingame, R W; Rubin, R L (1992) Anti-histone autoantibodies recognize centromeric heterochromatin in metaphase chromosomes and hidden epitopes in interphase cells. Hum Antibodies Hybridomas 3:40-7
Bell, S A; Hobbs, M V; Rubin, R L (1992) Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J Immunol 148:3369-76
Burlingame, R W; Rubin, R L (1991) Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 88:680-90
Roberts, D E; Peebles, C; Curd, J G et al. (1991) Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure. J Clin Immunol 11:389-97
Rubin, R L; Burlingame, R W (1991) Drug-induced autoimmunity: a disorder at the interface between metabolism and immunity. Biochem Soc Trans 19:153-9
Rubin, R L; Tang, F L; Tsay, G et al. (1990) Pseudoautoimmunity in normal mice: anti-histone antibodies elicited by immunization versus induction during graft-versus-host reaction. Clin Immunol Immunopathol 54:320-32
Burlingame, R W; Rubin, R L (1990) Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J Immunol Methods 134:187-99

Showing the most recent 10 out of 13 publications